# US 6,730,676 B2 · Pyrazino-pyridazine derivatives as ligands for GABA receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,676 B2
- Document ID: US6730676B2
- Status: Granted
- Kind: B2
- Application number: 10/168,234
- Filed: 2002-06-18
- Published: 2003-01-16
- Granted: 2004-05-04
- Earliest claimed: 2000-01-11
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: Wesley Peter Blackaby; Richard Thomas Lewis; Leslie Joseph Street
- Web page: https://patentgrep.com/patent/US6730676B2

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/26: Psychostimulants, e.g. nicotine, cocaine
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/16: Otologicals
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A class of pyrazino[2,3-d]pyridazine derivatives, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 5-position, a substituted alkoxy moiety at the 3-position, and a range of substituents at the 2-position, are selective ligands for GABAA receptors, in particular having high affinity for the α2 and/or α3 and/or α5 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.

## Claims

### Claim 1

A compound of formula I, or a salt thereof:
wherein:
Z represents C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, C6-8 bicycloalkyl, phenyl, naphthyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, diazepanyl, pyridinyl, quinolinyl, isoquinolinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinoxalinyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl, pyrazolyl, indazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, or di(C1-6)alkylamino, which groups are unsubstituted or substituted with one or more substituents selected from: C1-6alkyl, phenyl(C1-6)alkyl, naphthyl(C1-6)alkyl, pyridyl(C1-6)alkyl, halogen, halo(C1-6)alkyl, cyano, cyano(C1-6)alkyl, hydroxy, hydroxymethyl, C1-6alkoxy, C3-7 cycioalkyl(C1-6)alkoxy, C3-7 cycloalkoxy, amino(C1-6)alkyl, di(C1-6)alkylamino(C1-6)alkyl, di(C1-6)alkylamino-carbonyl(C1-6)alkyl, N-(C1-6)alkylpiperidinyl, pyrrolidinyl(C1-6)alkyl, piperazinyl(C1-6)alkyl, morpholinyl(C1-6)alkyl, di(C1-6)alkylmorpholinyl(C1-6)alkyl and imidazolyl(C1-6)alkyl;
R1 represents C3-7 cycloalkyl, phenyl, furyl, thienyl or pyridinyl, which are unsubstituted or substituted with one or more substituents selected from: C1-6alkyl, phenyl(C1-6)alkyl, naphthyl(C1-6)alkyl, pyridyl(C1-6)alkyl, halogen, halo(C1-6)alkyl, cyano, cyano(C1-6)alkyl, hydroxy, hydroxymethyl, C1-6alkoxy, C3-7 cycloalkyl(C1-6)alkoxy, C3-7 cycloalkoxy, amino(C1-6)alkyl, di(C1-6)alkylamino(C1-6)alkyl, di(C1-6)alkylamino-carbonyl(C1-6)alkyl, N-(C1-6)alkylpiperidinyl, pyrrolidinyl(C1-6)alkyl, piperazinyl(C1-6)alkyl, morpholinyl(C1-6)alkyl, di(C1-6)alkylmorpholinyl(C1-6)alkyl and imidazolyl(C1-6)alkyl; and
R2 represents C3-7 cycloalkyl(C1-6)alkyl, phenyl(C1-6)alkyl, furylmethyl, furylethyl, thienylmethyl, thienylethyl, pyrazolylmethyl, oxazolylmethyl, oxazolylethyl, isoxazolylmethyl, thiazolylmethyl, thiazolylethyl, imidazolylmethyl, imidazolylethyl, benzimidazolylmethyl, oxadiazolylmethyl, oxadiazolylethyl, thiadiazolylmethyl, thiadiazolylethyl, triazolylmethyl, triazolylethyl, tetrazolylmethyl, tetrazolylethyl, pyridinylmethyl, pyridinylethyl, pyridazinylmethyl, pyrimidinylmethyl, pyrazinylmethyl, quinolinylmethyl, isoquinolinylmethyl or quinoxalinylmethyl, which groups are unsubstituted or substituted with one or more substituents selected from: C1-6alkyl, phenyl(C1-6)alkyl, naphthyl(C1-6)alkyl, pyridyl(C1-6)alkyl, halogen, halo(C1-6)alkyl, cyano, cyano(C1-6)alkyl, hydroxy, hydroxymethyl, C1-6alkoxy, C3-7 cycloalkyl(C1-6)alkoxy, C3-7 cycloalkoxy, amino(C1-6)alkyl, di(C1-6)alkylamino(C1-6)alkyl, di(C1-6)alkylaminocarbonyl(C1-6)alkyl, N-(C1-6)alkylpiperidinyl, pyrrolidinyl(C1-6)alkyl, piperazinyl(C1-6)alkyl, morpholinyl(C1-6)alkyl, di(C1-6)alkylmorpholinyl(C1-6)alky and imidazolyl(C1-6)alkyl.

### Claim 2 (depends on 1)

The compound of claim 1 represented by formula IIA, and salts thereof:
wherein:
m is 1 or 2; and
R12 represents phenyl, naphthyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, diazepanyl, pyridinyl, quinolinyl, isoquinolinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinoxalinyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl, pyrazolyl, indazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, or tetrazolyl, which groups are unsubstituted or substituted with one or more substituents selected from: C1-6alkyl, phenyl(C1-6)alkyl, naphthyl(C1-6)alkyl, pyridyl(C1-6)alkyl, halogen, halo(C1-6)alkyl, cyano, cyano(C1-6)alkyl, hydroxy, hydroxymethyl, C1-6alkoxy, C3-7 cycloalkyl(C1-6)alkoxy, C3-7 cycloalkoxy, amino(C1-6)alkyl, di(C1-6)alkylamino(C1-6)alkyl, di(C1-6)alkylamino-carbonyl(C1-6)alkyl, N-(C1-6)alkylpiperidinyl, pyrrolidinyl(C1-6)alkyl, piperazinyl(C1-6)alkyl, morpholinyl(C1-6)alkyl, di(C1-6)alkylmorpholinyl(C1-6)alkyl and imidazolyl(C1-6)alkyl.

### Claim 3 (depends on 2)

The compound of claim 2 represented by formula IIB, and pharmaceutically acceptable salts thereof:
wherein:
Q represents the residue of a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, furyl or thienyl ring;
R3 represents hydrogen, methyl or fluoro; and
R4 represents methyl or ethyl.

### Claim 4 (depends on 3)

The compound of claim 3 wherein Q represents a cyclopropyl, cyclohexyl, phenyl, furyl or thienyl ring.

### Claim 5 (depends on 4)

The compound of claim 4 wherein R1 represents phenyl, fluorophenyl or difluorophenyl.

### Claim 6

A compound which is selected from the group consisting of:
2-cyclohexyl-3-(2-ethyl-2H-[1,2,4]triazol-3-ylmethoxy)-5-phenyl-pyrazino[2,3-d]pyridazine;
2-sec-butyl-3-(2-ethyl-2H-[1,2,4]triazol-3-ylmethoxy)-5-phenylpyrazino[2,3-]dipyridazine;
2-cyclopropyl-3-(2-ethyl-2H-[1,2,4]triazol-3-ylmethoxy)-5-phenyl-pyrazino[2,3-d]pyridazine;
3-(2-ethyl-2H-[1,2,4]triazol-3-ylmethoxy)-2-(furan-2-yl)-5-phenyl-pyrazino[2,3-d]pyridazine;
2-tert-butyl-3-(2-ethyl-2H-[1,2,4]triazol-3-ylmethoxy)-5-phenyl-pyrazino[2,3-d]pyridazine;
2-tert-butyl-3-(1-methyl-1H-[1,2,4]triazol-3-ylmethoxy)-5-phenyl-pyrazino[2,3-d]pyridazine;
2,5-diphenyl-3-(2-ethyl-2H-[1,2,4]triazol-3-ylmethoxy)pyrazino[2,3-d]pyridazine;
2,5-diphenyl-3-(1-methyl-1H-[1,2,4]triazol-3-ylmethoxy)pyrazino[2,3-d]pyridazine;
3-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-5-phenyl-2-(2-thienyl)-pyrazino[2,3-d]pyridazine;
and salts thereof.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

A process for the preparation of a compound of claim 1 which comprises reacting a compound of formula III (or its 2-hydroxypyrazino-[2,3-d]pyridazine tautomer) with a compound of formula IV:
wherein L1 represents a suitable leaving group.

### Claim 9 (depends on 1)

A method for the treatment of anxiety which comprises administering to a patient in need thereof an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
